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1 Zusammenfassung
Im Bereich der Krebstherapie gibt es derzeit massive Fortschritte, einschließlich der Felder
Strahlentherapie, Immunologie und Pharmakologie. Mechanismen der Therapiemethoden auf
der einen Seite und Mechanismen der Therapieresistenz werden immer klarer, was es er-
laubt Kombinationstherapien auf die immer noch immensen therapeutischen Herausforderun-
gen zuzuschneiden. Dies betrifft auch die Schwerionentherapie, die lokal sehr effizient ist,
deren systemische Wirkung aber noch weitgehend ungeklärt ist. Auf der zellulären Ebene
können Änderungen im Phänotyp der Tumorzellen zu einer besseren Erkennbarkeit durch
das Immunsystem führen - als Teil von Strahlenantworten and pharmakologischen Mecha-
nismen. In dieser Arbeit betrachten wir Phänotyp-Änderungen auf den murinen Tumor-
Zelllinien CT26.WT und 4T1 nach Bestrahlung mit Kohlenstoff - Ionen und Röntgenstrahlung
sowie spezifischer Inhibierung von c-Met, um einen Einblick in zugrundeliegende Mechanis-
men zu erhalten. Danach folgt eine Evaluierung von drei pharmakologischen Wirkstoffen, die
förderliche immunmodulierende Effekte gezeigt haben: Chloroquin, CDDO-Me und XL-184
(Cabozantinib). Daher wird hier die Hypothese aufgebracht, daß die immunstimulierenden
Eigenschaften, die jeweils in verschiedenen Modellen beschrieben wurden, in der Kombination
synergistisch wirken, da die Wirkmechanismen der einzelnen Substanzen verschieden und da-
her sehr wahrscheinlich nicht redundant sind. In der Kombination mit Kohlenstoffstrahlung
und Röntgenstrahlung wurde hierdurch im CT26.WT Zellen ein verstärkter Trend zu apopto-
tischem Zelltod festgestellt, während insbesondere Kohlenstoffstrahlung alleine eher zu einem
nekrotischen (Annexin-V negativem) Zelltod führte. In einem in vivo Modell für metas-
tatischen Brustkrebs (4T1) wurde gezeigt, dass XL184 das Tumorwachstum stark verringert.
Zusammenfassend könnte die Schwerionentherapie von dem hier vorgestellten Kombination-
sansatz profitieren, da die Zelltodmechanismen und damit die Immunogenität möglicherweise
unterschiedlich sind.
PhD Thesis
2 Abstract 1
2 Abstract
Tremendous progress is currently achieved in treating cancer, including the fields of radiother-
apy, immunotherapy and pharmacology. Mechanisms of therapy methods on the one hand
and treatment resistance mechanisms are increasingly elaborated, allowing to design combined
treatment approaches which address the tremendous therapeutic challenges still imposed by
many cancerous diseases. This also applies to heavy ion cancer therapy, which is very effec-
tive as a single modality treatment, but remains a localized treatment with unclear systemic
effects. On the cellular level, changes of phenotype could render tumor cells more visible to
the immune system, as part of the response to radiation and by pharmacological mechanisms.
In this thesis, we are looking at phenotype changes of murine tumor cell lines CT26.WT, 4T1
following x-ray and carbon ion irradiation as well as specific inhibition of c-Met, MEK and
Akt, in order to gain mechanistic insights. Three pharmacological agents are evaluated, which
did already show beneficial immune modulatory effects: Chloroquine, CDDO-Me and XL-184
(cabozantinib). Therefore, it is hypothesized here that the immune stimulatory properties
seen in different models by others could act synergistically, as the mechanism(s) of activity of
each compound are different and therefore most likely non redundant. In combination with
carbon ion irradiation and x-ray an increase in apoptotic cell death was found in apoptotic
cells, while carbon ion irradiation alone did rather lead to a necrotic (annexin-V negative) cell
death. In an in vivo model for metastatic breast cancer (4T1) it is shown that XL184 does
vastly reduce tumor growth. Conclusively, also heavy ion cancer therapy could potentially
draw benefit from the pharmacological approach presented in this thesis, as the cell death
mechanism and therefore the immunogenicity are potentially different.
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4 Introduction
Cancer [1,2] is caused by increasingly known [3,4] mutations of dividing stem cells [5], spurred
by external insults [6] and genetic predispositions [7]. The rapidly expanding knowledge en-
ables improved diagnosis [8,9], identification of new cancer drug targets [4] and tumor specific
antigens for immunotherapy [10,11]. Radiotherapy will benefit from inevitable [12,13] individ-
ualization of prescription doses and therapy decisions like choosing radiation qualities (e.g.
photons versus ions) [14,15] and allow for improved radiation risk estimates [16–18]. Although
progress in radiation oncology was driven mainly by physical developments [19] and cell intrin-
sic insights [20], research on cancerogenic, inflammatory insults, like viral [21,22] or bacterial [23]
infections, pointed to the role of normal host cells in cancerogenesis [24–26] and cancer pro-
gression [27–29]. With inflammation as a key process [24], the tumor microenvironment emerged
as a place reprogramming the host for metastasis [27], suppressing the immune system [30–32],
and providing growth factors to tumor cells [33]. Despite tumor heterogeneity [34,35], there is
optimism for targeted pharmacological management [36], as the diversity of mutations [4] is con-
verging on few increasingly druggable pathways [5] (see figure 1). With high mutational load,
responsiveness to immunotherapy is increasing [37]. But despite recent breakthrough successes
e.g. in melanoma [38], immune mediated cure is overall still rather an exception than a rule [39].
However, in cases like juvenile desmoid tumors with very few mutations and no well work-
ing drugs at hand [40], cure is readily furnished by protons [41] and carbon ions [42]. In more
challenging diseases like pancreatic cancer, carbon ion radiotherapy with concurrent immune
stimulating Gemcitabine [43] already furnishes a formerly unseen, but short two year median
survival of 43% [44]. Consequently, an integrated pharmacological approach can not be dis-
missed. [13,45].
Mimicking an immune activating, IFN-I dependent [46] viral insult [10] dependent on STING
signaling [46], the success of radiotherapy [47] and some types of chemotherapy [48] are also de-
pendent on the immune system. A key question is how to augment radiotherapy with phar-
macological and immunological optimization [13,45]. Clinical trials heading in this direction are
ongoing [49], and this is also the main motivation for this thesis.
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Scope of the Thesis and Choice of Compounds
From the situation as described above, we can conclude that there is a considerable chal-
lenge to appreciate innumerable different patient conditions which are vastly different from
one another. The range is from patients with extremely few tumor mutations up to several
thousands. It is currently unclear if it will ever be possible to find an effective drug related
answer to each of the patient situations. Also, it is currently mostly unclear, which treatment
approach, whether pharmacological, immunological or radiological can be most successful in
the respective cases. Most crucially, a lot of patients need solutions now.
This thesis is directed toward an integrated pharmacological approach, which aims to ad-
dress as many as possible challenges with as small as possible toxicity. Some of the challenges
are cell intrinsic, partly tumor cell intrinsic, and cell intrinsic concerning entire groups of nor-
mal host cells which can support tumor growth.
These issues are introduced in the following, divided in an in vitro and in vivo part. This is
followed by a pharmacological profile which is seen as a set of possible answers to the outstand-
ing questions described in these introductions. This is complicated by the fact that each and
any treatment, which is thought to act in one part of the host or tumor, inevitably will have
effects on other parts and situations. On the one hand, this can result in treatment related
complications. But on the other hand, treatment modalities which were thought to be cell
intrinsic are de facto effective by immune mediated mechanisms. This includes chemotherapy
and radiotherapy [50], as well as targeted treatments [51–53], which is now increasingly acknowl-
edged (see Figure 3 to give an example about how this potentially could look like).
The choice of compounds was to a vast degree met by considering pathways relevant for
tumor growth and immune suppression, which were integrated in a mindmap (http://radio-
immunology.org/Immunity_Irradiation_Cancer_by_Norman_Reppingen.pdf). In the case
of CDDO-Me, the Anderson Cancer Center published about 25 research papers exploring the
use and properties of this substance (personal communication with Michael Andreeff), encour-
aging its use to include it in radiotherapy settings.
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Figure 1: Brief overview of the interplay between radiation, molecular pathways and resistance
mechanisms. Molecules in blue color are the two most crucial tumor suppressor genes, the phosphatase
PTEN [54,55] and the key (but frequently mutated) transcription factor p53 [3,56,57]. Depicted in black are key
oncogenic molecules with their most frequent mutations [3] and ensuing treatment resistance mechanisms. GF:
Growth factors [33,58]; Molecules in red are receptor (upper row) and non receptor kinases. RTK: Receptor
Tyrosine Kinases [59], e.g.: Axl [60–62] Met, the receptor of the hepatocyte growth factor (HGFR) [63,64];
PDGFR [65], RET [66]; The following molecules are all (non receptor) kinases [67,68]: PI3K:
phosphatidylinositol-3-kinases [69–74]; Akt: Protein Kinase B [72,75–78]; Ras: Rat Sarcoma [79,80], the first
discovered oncogene [1,2], mutated in virtually all pancreatic cancers [81], some sarcomas [82] and others [3].
Worsening prognosis under SBRT conditions [83] and Y-90 radioembolization [84]. Targeting possible e.g. via
MEK-Inhibition [82,85] and Reoviruses with radiotherapy [86]. Raf : Acronym for Rapidly Accelerated
Fibrosarcoma, mutations very prevalent in melanoma [87–89]. MEK: Map Kinase which activates Erk (MAP-
Kinase Kinase, MAPKK) [90,91]; Erk1/2: extracellular signal regulated kinases [92], also called Mitogen Activated
Protein Kinases - MAPK [93–97] The following three molecules are key transcription factors for treatment
resistance: STAT3: Signal transducer and activator of transcription 3 [98–102,102–104]; NFκB: nuclear factor
κ-light-chain-enhancer of activated B cells [105]; Nrf-2: Nuclear factor (erythroid-derived 2)-like [106]; The following
three molecules are markedly anti-apoptotic: The Bcl-2 family [107] proteins BCl-XL & Mcl-1 [108] and the
IAP [109,110] group protein Survivin [111–116]; The only cell on the scheme, known for immune suppression (IS),
promotion of metastasis [117] and induction of Epithelial Mesenchymal Transition [118] (EMT): Myeloid Derived
Suppressor Cells (MDSC) [30–32,102]. Which can be antagonized e.g. by inhibition of B-RAF [119] and PI3Kγ [120]
with Gemcitabine [43,121] or by antagonizing G-CSF: Granulocyte-colony Stimulating Factor, a cytokine expanding
these cells [122], leading to invasion and metastasis [123]. ROS: Reactive Oxygen Species are tumorigenic e.g. by
oxidizing phosphatases [124] and driving inflammation [22], but are also critical effectors of x-ray
irradiation [13,57,125]. Carbon Ion Irradiation additionally [126] leads to excessive amounts of double strand
breaks [127] thus being 4-10 times more efficient than x-ray [13] and therefore relatively ignorant facing intratumoral
heterogeneity [128].
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4.1 in vitro
Encouragingly, oncogenic pathways in tumor cells, like PI3K [129], are important in inflamma-
tion [130] and immune suppression [24,120,131,132]. This reveals small molecule drugs [52,53] like
kinase inhibitors [68] as ideally suited to integrate into combined treatments [52]. Considering
figure 1, the branching point at the level of the RAS oncogene is upstream both of the Akt and
Erk/1/2 pathways. So, it is tempting to see results upon pharmacological treatment of both
pathways in parallel e.g. in cases of oncogenic RAS mutations [97]. This is one of the examples
of combined targeted therapy [133,134], which is also under investigation in combination with
x-ray irradiation [135]. The pathways in figure 1, and many more, are primarily considered
in terms of direct effects of tumor cell inactivation. For immune mediated cell killing, other
parameters are relevant, too. Some of these issues are now followed consecutively in the same
order as presented in the results and discussion parts.
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Phenotype changes
In order to find tumor cells, the immune system needs to recognize the tumor antigens arising
from mutations or translocations. During cancer progression, the immune system interacts
with the tumor both in terms of tumor promotion and desctruction, gradually enriching the
tumor in cancer cells it can no longer find, a process termed immunoediting [136]. This is
partly caused by a gradual decrease in MHC-I, the molecule responsible for immune recogni-
tion [121]. Therefore, loss of MHC-I is a treatment resistance mechanism in tumors [121,137]. Un-
der radiotherapy conditions in mouse models, immunity was shown to be mediated by CD8+
T-cells, to recognize tumor cells via antigen presentation on MHC-I [138–140]. Therefore, the in-
crease in surface presence of MHC-I is an attractive consequence of irradiation [13]. Phenotype
changes of tumor cells after x-ray irradiation with respect to upregulation of MHC-I [141,142]
and CD95 [143,144] have been observed, now also including proton irradiation [145]. CD95, also
known as Fas, is a death receptor that was shown to be involved with a select form of apop-
tosis, which can be immune stimulatory [146]. Carbon ions are here characterized for surface
translocation of CD95 and MHC-I using CT26.WT murine colorectal carcinoma cells and the
murine breast cancer cell line 4T1.
Autophagy induction
Autophagy has many functions in immunity and diseases including cancer [147], and is a point
of intervention in cancer therapy for its dichotomous, partly cancer promoting roles [148,149].
Autophagy is a process leading to the secretion of ATP, which attracts immune cells to the tu-
mor [150], which could also apply to radiotherapy [150]. Autophagy inhibition did show efficacy
in combination with MEK inhibition to restore the exposure of Damage Associated Patterns,
which could activate the immune system [151–154]. A most notable example which raised a lot
of attention was the doubling of median survival in Glioblastoma patients to 22 months, when
low dose Chloroquine was added to standard radiochemotherapy [155] - but the mechanism of
activity of chloroquine is still to be clarified (see below). Autophagy was shown to be a con-
sequence of both radiotherapy [156] and chemotherapy [157], resulting in surface translocation
of the Mannose-6-Phosphate Receptor, which was shown to be involved in immune mediated
tumoricidal effects [156,157]. Additionally, it has been shown that modulation of the autophagy
process with chloroquine was able to increase the effects of radiation in a immune depen-
dent manner, apparently by prevention of antigen degradation in the murine MCaK breast
tumor model [158]. Consequently, it is tempting to see in which ways autophagy modulation
by chloroquine could be useful, and how this could relate to heavy ion therapy.
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Dendritic Cell Maturation
The activation status of dendritic cells is considered the deciding factor in radiation induced
immune surveillance [139]. This has been shown to be dependent on cytosolic DNA sensing
of DNA from dead tumor cells by STING - signaling in dendritic cells [46,159] also following
irradiation [46]. TLR4 - signaling by radiation induced release of HMGB1 [151] was also shown
to have an influence [160], and other mechanisms of sensing apoptotic cells [161]. Direct irradi-
ation of wild type dendritic cells has been shown to upregulate the activation marker CD70,
but not CD80 on dendritic cells generated from monocytes from human donors, leading to en-
hanced T-Cell priming [162]. Others found an increase of CD80 on Dendritic Cells derived from
murine bone marrow upon irradiation [163]. It was shown that costimulatory signals via CD80
to CD8+ T-Cells were important for the immunogenicity of cis-platin based chemotherapy [48].
Molecular Mechanisms of surface exposure
A rational pharmacological augmentation of radiotherapy will probably be a lot easier knowing
the molecular mechanisms involved. Blocking MEK using the selective Inhibitor Trametinib
could vastly increase expression of MHC-I on CT26.WT cells [164]. In cases where irradiation
does not lead to a surface translocation of molecules relevant for dendritic cell activation or
tumor antigen recognition by T-Cells, appropriate pharmacological management could poten-
tially help to reinstate surface translocation of desirable molecules like MHC-I or CD95. On
the other hand, care should be taken with pharmacological agents which eventually interfere
in this process.
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Epithelial Mesenchymal Transition
Epithelial Mesenchymal Transition (EMT) is a process which is critical for tumor progres-
sion and metastasis, making cells motile and invasive [165], and is also implicated in Cancer
Stem Cell maintenance [29]. EMT is impairing immune mediated tumor cell lysis via induction
of autophagy [166] and is a process contributing to the formation of the immune suppressive
tumor microenvironment [167]. It is an inflammation driven process [167,168] and therefore a key
candidate mechanism of treatment induced cancer progression [169], including classical photon
therapy [170–174] and hyper-fractionated radiation [175], pointing to oligofractionation as a most
likely more favorable method. Epithelial Mesenchymal Transition is one of the most crucial
phenotype changes, and is therefore a key candidate for pharmacological management. As we
will see, selective inhibition of one single pathway could potentially be sufficient to defuse this
problem in many cases. Finding more relevant agents for management will be useful [176].
4.2 in vivo
As stated above, oncogenic pathways (figure 1) also reverberate in the tumor induced immune
suppression and other hallmarks of treatment resistance (figure 4). For some key players of
problems related to the tumor microenvironment, a short snapshot is given. This serves to
explain the choice of drugs which are evaluated in the in vivo part of this thesis, which are
described just after the features of TME related cells. Contrariwise to individual biomarkers,
which can only apply to few if not single patients, immune mediated mechanisms described
below are common schemes, deeply rooted in inflammation, and hence cancerogenesis.
Tumor Cell Death
Killing tumor cells is a central issue in cancer therapy and can be mediated by different cell
death modalities, e.g. apoptosis or necroptosis [149] and others [177]. Irradiation also can invoke
tumor cell death e.g. by necroptosis, extrinsic (CD95, DR5) and intrinsic (p53) apoptosis and
cell cycle arrest [57]. This can be hampered in cancer e.g. by genetic aberrations (deletion /
mutation of p53 in 50 % of cancer cases in general, 90 % in ovarian cancer in particular [3]),
which constitutes one of the hallmarks of cancer [29]. Radiation can also induce anti apoptotic
molecules (see figure 1 and 2) [101] even at very low radiation doses in the range of CT scans
(Survivin) [115]. Reinstating apoptosis is a desirable effect e.g. of Kinase Inhibitors [68]. Good
success was seen clinically with stereotactic beam radiation therapy (SBRT) and the apoptosis
inducing Tyrosine Kinase Inhibitor Sunitinib [178,179], which is directed e.g. against VEGF-R,
Kit and PDGFR [180]. Levels of the immune suppressive MDSC were used as a readout pre-
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dictive for therapy success [181]. A key point in tumor cell death modalities [177] is that tumor
cells dying apoptotically appear to be more efficient in inducing antigen cross presentation by
dendritic cells. Induction of apoptosis is a key point in anti tumor immunity, contrariwise to
cell death induced by necro(pt)osis [161,182]. Here, we first characterize apoptosis induction via
combined and specific targeting of MEK and c-Met in CT26.WT cells. Then we expand this
approach to CT26.WT, 4T1 and B16-F10 tumor cells with irradiation and pleiotropic agents,
as well as treating physiologically normal HMVEC cells.
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Figure 2: Depiction of cell death mechanisms [183], which show how molecules depicted in figure
1 can interfere with tumor cell death. Extrinsic apoptosis can be triggered by
death receptors [184,185] like DR-5 [185,186] and CD95 [143] via caspase 8 [152].
Intrinsic apoptosis follows stress responses, which can lead to a buildup of
p53 [187,188], with the DNA-damage response being most relevant for
radiotherapy [189,190]. Activation of p53 leads e.g. to GSK-3 [191] dependent expression
of PUMA [192]. So, the apoptosis ’inducer’ p53 is to a significant extent doing what
pro apoptotic pharmaceuticals do: Antagonizing anti - apoptotic BH3 only
proteins (e.g. Bcl-2, Bcl-XL, Mcl-1) [107], Erk1/2 [193] and other molecules
shown in figure 1. Another way to apoptosis induction is stress of the endoplasmatic
reticulum (ER-Stress) [194], which also can lead to a buildup of the pro apoptotic
molecule Bim [195]. Adding to apoptosis, p53 is steering a magnitude of other cell
processes [188]. It also can stall the cell cycle (CC) and clearly has functions beyond
these activities [196]. Both intrinsic and extrinsic apoptosis are converging on caspases
3 and 7. Granzyme A is activating a different cell death program dependent on
Reactive Oxygen Species (ROS), which is deployed e.g. by Natural Killer Cells, and
also leads, as apoptosis does, to phosphatidylserine outer membrane translocation
(Annexin-V - positivity) [197]. Necroptosis is a non apoptotic cell death
modality [198] triggered e.g. by TNF [199], leading to a homotrimer [200] of Mixed
Lineage Kinase Like (MLKL, blue donut trimer to the left) [201,202], perforating the
cell membrane (DAPI positivity) [200,203]. Necroptosis has key roles in
inflammatory diseases including rheumatoid arthritis [204], with ROS being
involved [205]. Ferroptosis, not depicted here, is also deemed pro inflammatory and
driven by iron, which leads to hydroxyl radicals via Fenton reactions, resulting in
lipid peroxidation [206]. Autophagy can be seen as a mechanism integrated between
the different cell death programs [207] and therefore shapes how these programs lead
to immunological responses and cancer metastasis [208]. Conclusively, the cell death
pathways play a crucial role in immunity in general [152], steer how radiotherapy is
influencing the immune system, and are therefore relevant for therapy success [209].
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The Tumor Microenvironment
The cell intrinsic issues mentioned above integrate in vivo in the tumor microenvironment
(TME) in a bidirectional way. The tumor microenvironment fuels the above mentioned issues
like EMT, invasive growth and apoptosis resistance. On the other hand, tumor cells manage
to attract cells from the bone marrow to support their growth [210]. The individual conditions
in the TME are now proven by big data efforts to decisively define disease prognosis [211,212],
metastatic dissemination [27,117], resistance to chemotherapy, targeted treatments [213], and ra-
diotherapy [214]. Consequently, tumors are increasingly seen as complex organs [29], giving rise
to cancer as a systemic disease. Encouragingly, the properties of the cellular constituents be-
come increasingly known [215], and offer useful mounting points for therapeutic interventions.
The in vivo efforts in this thesis aim to rewind some of the tumorigenic processes which are
prevalent in the TME per se, wich can be made worse and improved by radiation. Cancelling
out the adverse effects of radiation pharmacologically while optimizing the favorable effects
with radiation (fractionation, dose, quality [particles, photons]) could be a promising strategy,
here exemplified in the extremely aggressive, highly metastatic 4T1 model. Some key players
of the TME are briefly sketched out in the following, to explain some pharmacology deployed
in the field and attempts to approach these issue(s) this thesis.
Myeloid Cells
Myeloid cells are mostly discussed as Myeloid Derived Suppressor Cells (MDSC) and Tu-
mor Associated Macrophages (TAM) [216–220], are key players in cancer metastasis by immune
independent mechanisms [216,221], neoangiogenesis, as well as systemic [27] and local immune
suppression [28,117]. They are vastly expanded by cytokines, like (also radiation induced) [170]
G-CSF [221–223] even to the point of leukemia - like conditions [223]. The expanded MDSC
are attracted to the tumor e.g. by VEGF, as a consequence of tumor hypoxia related HIF-
signaling [224]. The function they are exerting is driven by growth factors like VEGF (both a
cytokine and a growth factor), PDGF, reactive species of nitrogen and oxygen [32].
Gemcitabine is a chemotherapeutic used concurrently with carbon ions e.g. in pancreatic
cancer [44] and was shown to be active against MDSC. This might explain parts of the efficacy
of this combination [43]. There have been incredibly good results in the notoriously aggressive
4T1 model, selectively antagonizing Myeloid Suppressor Cells (MDSC), leading to long term
surviving mice. However, success came with intermediary but great animal weight loss, re-
vealing both an important strategy and a need to be aware of toxicity in order to enable this
promising approach for patients [225].
Besides the notorious MDSC, which are recruited to the tumor in large numbers via radi-
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ation [226] Tumor Associated Macrophages (TAM) [217,218,220,227] are also immune suppressive
myeloid cells [217], frequently present in Tumor Microenvironment in a diversity of tumor enti-
ties [228], and contribute to neovascularization after radiotherapy [219]. They are also involved
in raising the fibrotic problems indicated below, e.g. supplying the tumor microenvironment
with PDGF [219]. However, they can be divided into tumor promoting M2 and tumor sup-
pressing M1 macrophages - termed macrophage polarization, which is a key factor in probably
all cancer therapies [227] . Crucially, this polarization appears to be flexible, allowing to turn
M2 into M1 macrophages, which could support therapy efforts. Low radiation doses, which
might not be very relevant for the usually higher doses in SBRT, can lead to a favorable
M1 polarization [229]. Contrariwise, therapeutic radiation could foster M2 polarization [219]
urging to adress this issue. In the 4T1 - Model, the tumor microenvironment is densely
populated by myeloid cells (MDSC/TAM) and very scarcely by T-Cells, reflecting the treat-
ment resistance mechanisms indicated above [224,230]. Therefore, appropriate pharmacological
macrophage management either by depletion or repolarization is seen with considerable hope
and has already shown efficacy [227]. Depletion of both MDSC and TAM with the shared
marker Gr-1 was able to decrease local recurrence after radiotherapy [231]. However, chosing
the right targets appears to be a crucial issue, as some treatment measures also can even
enhance metastatic spread and tumor growth [232].
Fibroblasts
are long known to radiation oncologists for their role in radiation fibrosis, a dreadful late
complication after radiotherapy [233,234]. More recently, it was revealed that cancer associated
fibroblasts in the tumor stroma strongly contribute to treatment resistance as a barrier to
chemotherapeutics and immune cells [235], being severely immune suppressive even when their
prevalence in the tumor stroma is as low as 2 % [236]. Even though most therapy measures to
date have been thought to be directed just against tumor cells, and tumor cells per se can also
be strongly immune suppressive [237], in the difficult KPC mouse model of pancreatic cancer,
selective depletion of FAP+ fibroblasts only, using CAR-T-Cells directed against FAP (and
hence no tumor cells), abrogated tumor growth [235]. Critically problematic for radiotherapy,
fibroblasts entirely retain their immune suppressive capability even after high SBRT - type
radiation doses [238], and radiation apparently can exacerbate metatasis enhancing properties
of fibroblasts [239].
So, we have clear evidence that it could be very helpful to antagonize fibroblasts. It currently
is unclear if we can have clinically approved measures directed against fibroblasts per se, and
the cellular interventions which have proven successful in mouse models [235] require highly
trained experts to be put into action, currently limiting a desirable broader use.
Potentially, it might be possible to target the inflammatory processes leading to fibroblast
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formation, which somehow mimic the processes leading to immune suppression [240]. Another
option is to intervene in fibroblast - mediated signaling, which can raise resistance against
targeted drugs [241]. For example, it was shown that targeting of PDGF-R allowed to strongly
ameliorate the induction of radiation induced fibrosis [242], in line with a report on PDGF-Rβ
as a marker of stromal activation [243].
T-Cells, specially CD8+ T-Cells, are key players in radiotherapy efficacy, and needed in
the tumor to augment the efficacy of radiotherapy [47,160]. The depletion of MDSC after high
dose irradiation in the CT26 model was shown to be dependent on CD8+ T Cells [160]. Some
tumors are devoid of T-Cells [244]. To change this is apparently a decisive effect of radio-
therapy [245,246]. Other cells influencing the tumor microenvironment [214,247,248], like immune
suppressive Mesenchymal Stromal (MSC) cells [249,250], which can be vastly increased in num-
bers in a CCL2 [251] dependent manner after irradiation e.g. to fuel neoangiogenesis [252], and
can expand MDSC via HGF/c-Met [253], cutting down on radiotherapy efficay.
Neutrophils [254], the most prevalent leukocytes, are still not clearly discernible from MDSC
and thus add to the MDSC conundrae [255].
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Pharmacological Management
Finding an integrated approach to match the challenges discussed above may seem like an ar-
duous task, and is taken up by international structured efforts [256]. However, many molecules
initially thought as target structures in cancer cells are also involved in tumor relevant sys-
temic processes (see above) and at the same time key features of FDA approved [257] targeted
drug regimens (see figure 3). Using the hitherto underestimated versatility of small molecule
drugs in immune modulation [52], a combination of three pharmacological entities was applied
to a small panel of representative tumor cell models and the murine 4T1 model of rapidly
metastasizing breast cancer, which invokes a massive expansion of MDSC [258] and is highly
resistant to therapy approaches [225,259]. Approaching this way has certain benefits of small
molecules:
Clinical experience with the drugs of choice is key for clinical translation.
Lower Toxicity, as immune modulation is different from direct tumor targeting.
Target diversity leaves tumors fewer options exploiting backup pathways.
Off target on purpose effects enable a multimodal approach (see figure 3).
The description below explains how the treatment modality of choice is thought to integrate
the challenges described above.
Cabozantinib (XL-184) is a Tyrosine Kinase Inhibitor (TKI) [260], approved for medullary
thyroid cancer, and shows activity in a diversity of Tyrosine Kinases (including all of the
Receptor Tyrosine Kinases shown in figure 1), amongst them RET (5.2 nM), MET (1.3 nM),
VEGFR2 (0.035 nM), KIT (4.6 nM) [261,262], Tie2 and PDGF-R [257]. Despite it is viewed
mainly as a anti vascular agent for its VEGFR2 - inhibiting properties [248], targeting of VEGF
also strongly reduced the prevalence of myeloid cells in the 4T1 model [224]. Adding to a reduc-
tion of myeloid cell numbers, XL-184 was shown to enrich the tumor microenvironment with
both CD4 and CD8 T-Cells, and did demonstrate immune mediated activity in the MC38
model of colorectal carcinoma [263]. Its reported activity against PDGF-R could potentially
be of interest to antagonize (also radiation induced) fibrosis [242]. XL-184 was shown to de-
rail the cancer promoting crosstalk between fibroblasts and tumor cells in a HGF dependent
manner [264], and therefore potentially could reduce the MET dependent expansion of MDSC
via MSC derived HGF [265]. This could be highly attractive in radiotherapy, as MSC can be
recruited to tumors via irradiation [252], where they could contribute to the buildup of fibrob-
lasts, which are, as stated above, key players in treatment resistance [266,267]. Adding to HGF,
Angiopoetin is another growth factor secreted by MSC which can expand myeloid cells via the
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Tie2 receptor [249], another kinase target of XL-184 [257]. Sunitinib was shown earlier to have
useful immune modulatory properties, and is in so far successful studies to augment SBRT.
However, Sunitinib is not an inhibitor of c-Met. This property can be particularly useful
for radiotherapy, as HGF [268] and PDGF [269] signaling is kind of a hypoxia induced backup
pathway for angiogenesis [268].
Most crucially, c-Met is shown by a huge body of evidence to be relevant across practically
all cancerous disease entities, and highly involved in disease progression [270]. Targeting c-Met
specifically was shown to induce DNA damage related senescence in a radiosensitizing man-
ner [271], rendering this drug target particularly interesting for heavy ion radiotherapy.
The c-Kit - Inhibition by Imatinib, which shares a lot of kinase targets with XL-184 (c-Kit,
PDGFR, VEGFR...) [257], was shown to antagonize regulatory T-Cells via suppression of in-
doleamine 2,3 - dioxygenase (IDO) [272], a molecule involved in MDSC recruitment in a Treg
dependent manner [273]. Conclusively, also in highly tumor targeted agents, there is a lot of
room for immune modulatory activities (see Figure 3) [52].
Figure 3: XL-184 (Cabozantinib) did show activity against about 80 kinase targets in a cell
free assay [257] and was shown to be immune activating [263,274]. Here depicted is a
selection of its targets mapped to possible mechanisms. (Tyro3, Axl and Mer) [275],
Flt-3 [276], Ron [277], PDGFR [242], Tie2 [278], RET [66], c-Met
(http://www.vai.org/met/) [279,280], Btk [281,282]. However, the activity against Flt3
could hamper DC function [283].
CDDO-Me is a semisynthetic triterpenoid [284] with a multitude of tumoricidal properties [284,285],
acting pro apoptotic in many tumor cells and preventing epithelial mesenchymal transition [286].
It is a strong activator of Nrf-2, and was shown to block immune suppressive functions of
MDSC in some mouse models and a small patient group in a non toxic manner [287]. It was
demonstrated to repolarize tumorigenic M2 to tumoricidal M1 macrophages [288]. As radia-
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tion induced long-term intestinal adverse effects have surpassed inflammatory bowel disease
in incidence [289], the high efficacy against radiation induced inflammation and tissue damage
is particularly interesting [290–292]. With inflammation being a key driver of carcinogenesis [24],
the efficacy in reducing radiation related carcinogenesis [293] and x-ray related fibrosis [294] is
revealing CDDO-Me et al. very interesting for improving radiotherapy. CDDO-Me did show
anti metastatic properties in the 4T1 model as liposomal formulation [295]. However, as a note
of caution, Nrf-2 inducers could potentially also protect tumor cells from radiation, potentially
necessitating patient stratification [296].
Chloroquine is now being used as an anti inflammatory drug against arthritis with very ac-
ceptable side effects [297]. It was able to double the median survival of glioma patients together
with chemoradiation [155] and improved the immunogenicity of radiation in the murine MaCaK
model of breast cancer [158]. It also was shown to improve CD8+ mediated immunity [298,299].
Chloroquine was shown to ameliorate the metastasis-enhancing properties of fibroblasts in the
4T1 model by anti inflammatory mechanisms [239], and was shown to confer Notch-dependent
tumor vessel normalization [300]. However, despite reports of anti metastatic activity in the
4T1 model [239,301], Chloroquine did not show impressive activity in 4T1 tumor growth with or
without radiation [302]. Nevertheless, as a safe adjunct component its benefit could outweigh
the risks.
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5 Results
5.1 Phenotype changes of tumor and immune cells
The murine tumor cells chosen for this experiments are hallmark model systems in immunology,
and extensively characterized. The U2OS cell line stably transfected with LC3-GFP-RFP
enables to follow location and function of autophagic vesicles by microscopy. The murine
tumor cells used in this thesis represent a spectrum of different properties with respect to
the p53 mutation status, the mutation load and hence their immunogenicity. CT26.WT cells
overexpress wild type p53 [303], B16-F10 cells express p53 mutated in the DNA binding region
and mutated PTEN [304], whereas 4T1 cells are p53 protein negative [305]. About half of tumors
express mutated p53. Given the role of p53 in apoptosis induction (see figures 1 and 2) and
immunity [306], p53 status is a central determinant in treatment responses [306]. This section is
mainly thought to evaluate the phenotype changes of these test systems to different treatment
cues.
5.1.1 Exposure of MHC-I and CD95 after x-ray and carbon irradiation on CT26.WT
cells
In the murine CT26.WT colorectal carcinoma cell line, which is triploid in double mutated K-
Ras (V8M, G12D) [303], x-ray - irradiation (figure1) did result in an increase in surface presence
of MHC-I (figure 4). Irradiation with carbon ions did lead to a smaller increase in surface
translocation, which demonstrated a saturation at rather small doses of approximately 2-3
Gy (figure 5). The smaller tendency of carbon ion irradiation to induce surface translocation
compared to x-ray was also found for the death receptor CD95, and was also seen in many
other FACS - Samples, of which representative examples are shown.
Figure 4: Exposure of MHC-I and CD95 on CT26.WT cells 24h after x-ray irradiation (n=3).
Error bars represent the standard deviation of three measurements from one
representative experiment.
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Figure 5: Exposure of MHC-I and CD95 on CT26.WT cells 24h after carbon ion irradiation
(n=3) The LET was 325 keV/µm. Error bars represent the standard deviation of
three measurements from one representative experiment.
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5.1.2 Exposure of MHC-I and CD95 after x-ray and carbon irradiation on 4T1 cells
In the 4T1 cell line, x-ray irradiation did not lead to a surface translocation visibly different
from carbon ions. However, a smaller number of samples was screened for the 4T1 cell line. In
comparison to the CT26.WT cell line, also in other x-ray experiments, the surface translocation
appeared to be generally rather small on the 4T1 cell line (figure 6).
Figure 6: Exposure of MHC-I and CD95 on 4T1 cells 24h after x-ray- (left) and carbon ion
irradiation (right, LET= 325 keV/µm). Error bars represent the standard deviation
of three measurements from one representative experiment.
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5.1.3 Induction of autophagy in U2OS cells via x-ray and carbon ions
Autophagy is a process inducible via irradiation [156] as well as chemotherapy [157], and con-
tributes to the immune mediated effects of these standard therapy measures. Therefore, it is
attractive to have access to methods to explore autophagy. The effect of 10 Gy X-Ray irradi-
ation after 24 h is here demonstrated with U2OS - cells of human osteosarcoma, transfected
with LC3 fused to GFP and RFP. To the best of my knowledge, this test system has not been
subjected to irradiation so far. Acidification of the induced autolysosomes upon autophagy
induction leads to a quenching of the green fluorescence, with the red signal remaining intact,
visible per microscopy (see red arrows on figure 7). With carbon ion irradiation, no increase
in red spots could be seen with doses ranging from 1 to 30 Gy after one experiment.
Figure 7: Induction of Autophagy in U2OS cells transfected with LC3-GFP-RFP 24 h after 10
Gy of x-ray. The irradiated sample (lower right) does show an increased abundance
of acidic vesicles visible only in the red channel (red arrows). In control samples,
fewer acidic vesicles are visible (upper right). The signal in the green channel is
quenched as described in the text in the case of autophagically active vesicles. The
cells were kindly provided by Oliver Kepp from the Group of Guido Kroemer,
UMR1138 équipe 11, Centre de Recherche des Cordeliers, 15 Rue de l’École de
Médecine, 75006 Paris France.
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5.1.4 Switch from mesenchymal to epithelial phenotype via MEK - Inhibition
MEK is a crucial MAP Kinase and therefore a central signaling molecule in tumor cells (see
figure 1), and therefore a candidate drug target for combination therapies. Treating CT26.WT
cells with the MEK inhibitor Trametinib, a change to an epithelial phenotype was noted (figure
8), and found to be in line with publications in other cells, referring to cells with mutated
BRAF subjected to MEK inhibition [307] and KRAS-mutated cells to Erk1/2 inhibition [308].
Figure 8: Switch from mesenchymal (left) to epithelial (right) phenotype via MEK - Inhibition
in CT26.WT cells after 24 h with 100 nM of Trametinib.
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5.1.5 Apoptosis induction via X-Ray and combined Inhibition of MEK and Met
CT26.WT cells were incubated for 20 h with each 100 nM of Trametinib, a selective Inhibitor
of MEK (see figure 1), and EMD1214063, a selective inhibitor of c-Met [309] (see figure 1). Cells
were irradiated with 10 Gy and after 24 h analyzed with DAPI and Annexin-V - staining for
evaluation of necrotic and apoptotic cells. Despite the response at this time point was quite
low, with only few detectable apoptotic cells, it is suggesting an additive effect of the treatment
measures in this preliminary experiment (figure 9).
Figure 9: FACS plots of DAPI and Annexin-V stained CT26.WT, incubated as indicated,
irradiated with x-ray after 24 h and worked up for analysis after media change and
24 h of further incubation.
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5.2 Translational approach, in vitro
The above mentioned experiments refer to single molecules and readily discernible mechanisms,
using selective inhibitors. In contrast, the drug regimen chosen for the in vitro- and in vivo
experiments is highly pleiotropic - a concept termed polypharmacology [4]. The results are
characterized in the following via DAPI / Annexin - V - staining in three tumor cell lines
and human microvascular endothelial cells representing normal tissue, western blot analysis of
cancer cell survival pathways and surface exposure of immune relevant molecules on CT26.WT
cells.
5.2.1 Induction of Cell Death in CT26.WT tumor cells, x-ray and carbon ion
experiments
CT26.WT cells were incubated with Chloroquine, CDDO-Me and XL-184 at the indicated
concentrations for 20 h, irradiated with the indicated doses and submitted to FACS - Analysis
after 24 h. Adding to an apparently high background of necrotic Propidium Iodide+ cells,
upon combination of all three drugs a population of cells positive both in Propidium Iodide
and Annexin-V staining emerged with and without irradiation (figure 10).
Figure 10: FACS - plots of Propidium Iodide (PI) / Annexin-V stained CT26.WT cells after
drugging with the indicated drugs and x-ray irradiation, concentrations and
radiation doses.
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In a representative experiment with carbon ion irradiation, a shift from necrosis to apoptosis
was also visible under influence of the drugging regimen with the same drug concentrations
as in the x-ray experiments (figure 11).
Figure 11: FACS - plots of Propidium Iodide / Annexin-V stained CT26.WT cells after
drugging with Chloroquine, CDDO-Me and XL-184 for 20 h as above and
irradiation with carbon ions. The LET was 168 keV/µm.
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5.2.2 Induction of Cell Death in B16-F10 tumor cells (x-ray)
B16-F10 cells are a frequently used model for melanoma in preclinical research, and able to
undergo apoptosis. B16-F10 cells were treated as the CT26.WT cells, with the difference of a
lower concentration of XL-184 of 2.5 µM. Despite this dose reduction, a pronounced response
was found also in this cell line, indicating late apoptosis. The combination of all three drugs
also here led to the presence of apoptotic cells in a way much more pronounced in comparison
to the individual treatments (figure 12).
Figure 12: FACS - plots of DAPI / Annexin-V stained B16-F10 cells after drugging and
irradiation with the indicated drugs, concentrations and radiation doses.
Measurement took place 24 h after irradiation as for the other cell lines. The data
was raised with technical assistance from the master students Dominique Tandl and
Tobias Schulze (TU Darmstadt).
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5.2.3 Induction of Cell Death in 4T1 tumor cells (x-ray)
4T1 cells are a frequently used model for metastatic breast cancer in preclinical research, and
are not prone to undergo apoptosis. Despite the 4T1 cells were treated like the B16-F10 cells,
the response was different to the results above. Annexin-V positive cells were barely visible
in any of the treatment condition neither with nor without radiation. The most pronounced
response resulting in DAPI positive necrotic cells was seen with XL184 and irradiation without
other drugs. In the experiment, this treatment group was part of a duplicate with a similar
result (figure 13).
Figure 13: FACS - plots of DAPI / Annexin-V stained 4T1 cells after drugging and x-ray
irradiation with the indicated drugs, concentrations and radiation doses.
Measurement occured 20 h after irradiation.
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5.2.4 No Induction of Apoptosis in HMVEC normal tissue cells
Human microvascular endothelial cells (HMVEC) of low passage number were treated similar
to the B16-F10 and 4T1 cells using 2.5 µM XL-184. In all treatment groups including the
samples irradiated with 10 Gy x-ray, cell death as assessed via DAPI / Annexin-V staining
remained above below 5 %, revealing no apparent signs of toxicity (figure 14).
Figure 14: FACS - plots of DAPI / Annexin-V stained HMVEC normal tissue cells after
irradiation with x-ray and treatment with the indicated drugs, concentrations and
radiation doses.
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5.2.5 Anti apoptotic and oncogenic molecules in CT26.WT cells
CT26.WT cells were incubated with Chloroquine (CQ) [5 µM], CDDO-Me [150 nM] and XL-
184 [3.3 µM] for 44 h and subjected to Western Blotting. Values were normalized to untreated
cells, blotting was carried out in technical triplicates with material from one experiment.
Apparently, XL-184 has an effect of diminishing Erk/1/2 phosphorylation levels, whereas
CDDO-Me was reducing the abundance of molecules known for derailing apoptosis, namely
Bcl-XL, Mcl-1 and Survivin. There was also a visible but less pronounced effect of CDDO-Me
on the abundance of phosphorylated Akt and phosphorylated STAT3. The lowest values of 20
% in the densitometric measurements appeared to be close to background levels. Densitometric
values were normalized to the signal of vinculin as house keeping gene, and the values of the
drugged cells were normalized to the values of untreated cells (figure 15).
Figure 15: A: Densitometric data collected from western blots performed in technical
triplicates from one experiment. CT26.WT cells were drugged for 44 h as indicated.
B: Exemplary western blot with 7.5 µg of total protein being applied per each lane.
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5.3 Translational approach, in vivo x-ray
Two in vivo experiments were carried out to evaluate the efficacy of the drugging regimen in
the highly metastatic 4T1 model of breast cancer, which is highly resistant against basically
all therapy measures [225]. The few success stories were bought with arduous toxicity [225,259],
including temporary weight loss of more than 20 % [225]. In the first experiment, many different
treatment groups were evaluated. In the second experiment, the focus was put on XL-184,
which revealed the most pronounced effect.
5.3.1 In vivo Experiment I
Dosing was 10 mg per kg body weight for XL184 and Chloroquine and 50 mg per kg body
weight for CDDO-Me. Drugging was started at day 10 after tumor inoculation, irradiation
with a dose of 10 Gy from one side took place on day 14. The reduction of tumor growth was
most pronounced in the group treated with XL-184, with no evident influence of the radiation
at day 19 (figure 16). Interestingly, the combination of the three drugs did not lead to an
additive effect, which somehow reflects the results in the in vitro setting. For CDDO-Me alone,
the tumor growth curve was practically identical with the control group (data not shown).
Instead of an effect on the tumor growth, the mice receiving any CDDO-Me containing diet
responded with weight loss of about 10 % (data not shown). The irradiated groups receiving
control diet and CDDO-Me treated diet were lost shortly after irradiation demonstrating severe
symptoms of illness and dramatic weight loss, which led to termination of the experiment at
day 19. A difference in lung metastasis count was not seen under these conditions (data not
shown).
In the other treatment groups, the effect on tumor size was between the control group and the
groups treated with XL-184, pointing to no additive or otherwise increased effect (figure 17).
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Figure 16: Tumor growth kinetics of 4T1 tumors under influence of drugging with XL-184
starting at day 10 and irradiation with 10 Gy x-ray at day 14. Each group did
consist of 8 animals.
Figure 17: Tumor growth kinetics of 4T1 tumors under influence of drugging with XL-184,
CDDO-Me and Chloroquine starting at day 10 and irradiation with 10 Gy at day
14. Animal work was carried out under the responsibility of Jutta Petschenka by
TRON GmbH.
5.3.2 In vivo Experiment II
In the second experiment, the beginning of the drug treatment was started at day 5 after
tumor inoculation. The radiation dose was increased to 14 Gy. Irradiation also took place on
day 14. The number of treatment groups was narrowed down to the control groups and the
treatments which included XL-184. The treatment groups 1 and 2 did consist of 13 animals,
the other groups of 8 animals per each group (figure 18).
All treatment groups showed slower tumor growth than the control group (figure 18). The
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Figure 18: Tumor growth kinetics of 4T1 tumors under influence of drugging with XL-184,
CDDO-Me and Chloroquine starting at day 5 and irradiation with a dose of 14 Gy
x-ray at day 14 after tumor inoculation. Animal work was carried out under the
responsibility of Jutta Petschenka by TRON GmbH.
irradiated group (14 Gy on day 14) showed only a small difference to the control group till
day 19, with the difference getting more pronounced at day 21. The strongest tumor growth
reduction was found in the group treated only with XL-184. In the group where XL184 and
irradiation was combined, irradiation did not lead to further tumor growth reduction in com-
parison to the group treated with XL184 alone. Treatment of the tumors with all three drugs
and irradiation revealed a tumor growth reduction compared to the control group. However,
the effect was inferior to the growth reduction with XL-184 alone.
At day 19, the groups revealed a two star significance in the ANOVA test for difference
among the means of the groups (P = 0.0038). For the groups treated with XL184 and XL184
+ 14 Gy, at day 19 the Mann-Whithney - test revealed significance with a P of 0.0056 and
0.0063, respectively, concerning the difference to the control group. The difference of these two
treatment groups to the control groups increased at day 26, with a statistical significance of P
= 0.0002 and P = 0.0006, respectively. The Mann-Whitney test was resulting in significance
(P = 0.017) in the group which was not irradiated but treated with all drugs in comparison
to the control group. At day 26, the difference of the irradiated group to the control group
was not statistically significant (figure 18).
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Upon resection of tumors and organs, the lungs of all animals were infused with blue ink and
the now visible superficial metastases were counted without microscopic aid. Also with the
now extended observation time frame compered to the first in vivo experiment, no relevant
difference in lung metastases count was seen (figure 19).
Figure 19: Superficial lung metastases were counted macroscopically in all animals of each
group after sacrifice on day 26 after tumor inoculation. Each data point represents
the number of counted metastases in one animal. Groups 2, 4 and 5 were irradiated
with 14 Gy of x-ray irradiation from a 320 kV x-ray tube.
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6 Discussion
6.1 Phenotype changes of tumor and immune cells upon irradiation
6.1.1 Exposure of MHC-I and CD95
The comparison of x-ray and carbon ion irradiation revealed a somewhat inferior ability of
carbon ions to induce surface translocation of MHC-I and CD95 in CT26.WT cells (figures 4
and 5). From a perspective of immune surveillance, this might be seen as a disadvantage, as
less MHC-I on tumor cells will not improve tumor antigen recognition [121]. In the preliminary
measurements with 4T1 cells, a difference in the generally low surface translocation between
x-ray and carbon irradiation was not visible (figure 6). However, the exploration of immune
relevant molecules in the tumor microenvironment after irradiation has only begun [214,310],
and huge differences between in vivo and in vitro results were seen for surface translocation
of immune relevant molecules [311]. So, the difference between in vitro work and in vivo reality
can by far exceed the difference between radiation qualities. Therefore, a deeper exploration
of radiation effects on tumor cells and their surrounding stroma in immune competent and
-incompetent models side by side could be a way to increase the insights.
6.1.2 Induction of Autophagy
Mechanistically, it is interesting that pharmacological inhibition of mTor e.g. with rapamycin,
which usually leads to the induction of autophagy, has been shown to decrease MHC-I sur-
face translocation [312], while irradiation [312] including carbon ion irradiation is increasing it.
However, upon carbon ion irradiation, no excessive amount of LC3-RFP - spots indicating
autophagy were spottet in U2OS cells at doses up to 30 Gy after 24 h in one experiment.
Contrariwise to the results with carbon ion irradiation, there was a response 24 h after 10 Gy
of x-ray (figure 7). On the other hand, there are reports of autophagy induction via carbon
ion irradiation in other tumor cell lines [313,314]. For my experiments, only one cell line was
at hand, so a systematic exploration of dose and radiation quality dependence in autophagy
induction and exploration of mechanisms in more models could be useful.
6.2 Characterization of Molecular Mechanisms
The apparently lower propensity of carbon ions to induce an enhancement of MHC-I surface
presence on tumor cells (figures 1 and 2) suggests, that an increase by pharmacological means
could be a useful way to complement carbon ion therapy - apparently even more than in the
case of classical photon therapy. Therefore, more knowledge on the molecular mechanism of
surface translocation is needed. To approach this challenge, the CT26.WT colorectal carci-
noma cell line, which is triploid in double mutated K-Ras (V8M, G12D, see figure 1) [303], was
treated with a set of highly selective inhibitors of pathways perpetually active in this cell line
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(see also figure 1). Preliminary results showed an increased MHC-I surface translocation after
selective MEK - Inhibition (data not shown).
6.2.1 Switch from mesenchymal to epithelial phenotype via MEK - Inhibition
The experiments with the MEK inhibitor trametinib revealed an interesting phenotype change
from the spindle shaped, mesenchymal CT26.WT cells [315] to a flat, epithelial phenotype
(figure 11). Inhibition of MEK [307] and Erk1/2 [308] was shown in other cell types to reverse
epithelial to mesenchymal transition (EMT) [118,165], though not in this readily visible manner.
EMT is a radiation inducible [174] signaling program involved in invasive growth, and therefore
cancer metastasis [316]. Inhibition of Erk1/2 (downstream of MEK, see figure 1) was shown
to reverse invasive growth [317], in line with this visible phenotype change. Because of its
involvement in disease progression, treatment resistance and worsened prognosis, pathways
involved in EMT are now associated to the cancer stem cell [316,318,319], which is considered a
’cornerstone of radioresistance’ [320]. Adding to that, EMT is now increasingly recognized as a
resistance mechanism to immune therapy [166,321,322], and also relevant for radiotherapy [174].
6.2.2 Apoptosis induction via X-Ray and combined Inhibition of MEK and Met
Targeting treatment resistance pathways to enhance radiotherapy efficacy is an upcoming chal-
lenge. Inhibition of MEK was shown to sensitize K-RAS mutant cell lines for radiation [323],
and is here combined with selective inhibition of c-Met. C-Met is a radiation- [324] and hy-
poxia [268] inducible drug target involved in EMT, CSC properties and radioresistance [320].
Therefore, inhibition of c-Met is also seen as a tool for sensitizing c-Met positive cancers to
radiation [63]. Irradiation of drugged and undrugged cells and combined treatment with the in-
hibitors did show a modest increase in apoptotic cells after 24 h in this preliminary experiment
(figure 12). K-RAS mutations were reported to confer resistance to Met Inhibition [325], which
was apparently not vastly improved targeting MEK in this relatively strongly mutated cell
line as predicted by the transcriptome [303]. Given the inherent heterogeneity of evolving [35]
tumors [326] and the tumor microenvironment [248], it is foreseeable that single target selective
inhibitors will meet limitations. Additionally, conditions like hypoxia and radiation could in-
duce even more cancer promoting pathways, leaving loopholes for tumor recurrence. The role
of apoptosis induction is not restricted to direct effects of drugs and / or radiation,but also
seen as an immune relevant process, as apoptotic cells were shown to be more likely to activate
dendritic cells, enhancing their cross presenting activities [146,182]. This does apparently not
apply to necrotic cells in the same way [161,327]. This means that more efficient induction of
apoptosis is desirable, which probably could be furnished more straightforwardly by agents
with multiple drug targets, which also strike more or less generally abundant features of the
tumor microenvironment (see figure 4).
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6.3 Translational approach, in vitro
Three drugs chosen mainly for their reported immune modulatory properties (see introduction)
were characterized for their direct effects on different murine tumor cells, regarding their
influence on apoptosis. Evaluation on possible toxic effects was carried out using neonatal
human microvascular endothelial cells (HMVEC), representing normal tissue.
6.3.1 Induction of Cell Death in murine CT26.WT, B16-F10 and 4T1 tumor cells
In CT26.WT colorectal carcinoma cells and B16-F10 melanoma cells, the combination of
plasma typic doses of chloroquine, CDDO-Me and XL-184 (cabozantinib) did reveal an in-
crease in dead tumor cells which was more pronounced in combination with x-ray irradiation
(figures 13 and 15), and even further increased with heavy ions (figure 14). This was also the
case in combination with carbon ion irradiation in experiments with CT26.WT cells, which
were the focus cell line in the in vitro experiments, also because of the comprehensive char-
acterization of this cell line [303]. In the B16-F10 murine melanoma cell line [304], this efficacy
could potentially be ascribed to high levels of c-Met and Axl as seen in the transcriptome,
rendering the cells susceptible to XL-184, which is targeting Met, Axl, and all the other re-
ceptor tyrosine kinases depicted in figure 1.
In the 4T1 cell line, the behavior was different. XL-184 alone did show cell killing capa-
bilities superior to the triple combination under irradiation conditions. Additionally, on 4T1
cells, there was nearly no Annexin-V detectable under any evaluated experimental conditions
with and without x-ray irradiation (see figure 16). This is resembling the reported reluctance
of 4T1 cells to undergo apoptosis after irradiation, tested with caspase inhibitors, which did
not influence irradiation induced cell death [328]. p53 is amongst the most frequently mutated
tumor suppressor gene in about half of all cancer cases [283], and nearly all of ovarian cancers [3].
In B16-F10 cells, p53 is present, but mutated in the DNA binding region [304]. The B16-F10
melanoma cells did show a pronounced apoptotic response to radiation with chloroquine,
which was reported to support p53 mediated apoptosis in glioma cells [329]. In melanoma,
chloroquine activity was also ascribed to autophagy inhibition [330] and lysosomal membrane
destabilization [331]. Radiosensitization by chloroquine was reported back in 1973 [332].
CT26.WT, which responded with apoptosis, is expressing wild type p53 [303]. Unlike the 4T1
cell line - in which p53 protein is generally absent [333]. This result is reflecting the notion that
the plethora of observed p53 mutations does not necessarily hamper tumor cell apoptosis [3], as
apoptosis (at least, Annexin-V surface translocation) was seen in B16-F10. But it also lends
one more explanation for the excruciating resistance of the 4T1 model to radiotherapy [259],
immune therapy [283] and chemotherapy, given the role of p53 in the induction of cell intrinsic
apoptosis [56] and cell cycle arrest (see also figure 1). Consequently, the combination of the
three pharmacological entities did show in vitro efficacy in apoptosis competent tumor cells.
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6.3.2 No Induction of Apoptosis in HMVEC normal tissue cells
Treatment limiting toxicity is a topic of concern also in combined treatments, and in the case
of Sunitinib directed against VEGFR2 (and c-Kit and others), dose reductions were made
in conjunction with stereotactic body radiation therapy [179], where high, ablative doses are
applied to the tumor [153]. Therefore, it could be useful to apply therapy measures directed
against tumor cells to physiologically normal cells, to get at least a rough idea about normal
tissue toxicity. Drugging HMVEC with a cocktail of Chloroquine [5 µM], CDDO-Me [150 nM]
and XL-184 [2,5 µM] did not result in a lot of dead cells, at least 95 % of cells were surviving
with and without radiation and / or drugging (figure 17). A clinical dose reduction trial
was untertaken with XL-184 in colorectal cancer without radiation, and did show sustained
treatment efficacy despite the dose reduction to 40 mg per day [334]. This is pointing to a
possibility to augment radiotherapy in a tolerable manner. Drug induced toxicities are very
prevalent also with targeted agents [335] and combined toxic effects of targeted therapies with
x-ray can e.g. severely affect the skin [336]. Therefore, carbon ion therapy with its precise
dose applicability and lower skin dose could be superior in preventing toxicities of combined
treatments. More test systems for such questions could be useful.
6.3.3 Western Blot Analysis of anti-apoptotic molecules, p-Akt, p-Erk & p-STAT3
As CT26.WT is highly expressing wild type p53 [303], the question could be raised why it is
difficult to drive CT26.WT cells into apoptosis via irradiation, where it overall rather acts
via necroptosis, which is immunologically less favorable [146,161,182,327]. The transcriptome of
CT26.WT [303] hinted to an overexpression of the antiapoptotic molecules indicated in figure
1 and the tyrosine kinases Met and Axl (see figure 1). As we could see apoptosis under the
drugging regimen, western blot analysis was undertaken to characterize the protein levels of
Bcl-XL, Mcl-1, and Survivin and the phosphorylation states of p-Akt, p-STAT3 and p-Erk1/2
(see results on figure 18), which all are considered to contribute to disease progression and
therapy resistance (see figure 1 and figure 2). The drugging regimen was as above consisting
of chloroquine [5 µM], CDDO-Me [150 nM] and XL-184 [3,3 µM] and was applied for 44 h to
CT26.WT cells. The western blot analysis, carried out at least in triplicates but only from
one experiment, revealed a reduction of the protein levels of BCl-XL, Mcl-1, and Survivin
which was attributable mainly to CDDO-Me, as well as a reduction in phosphorylated Akt
and STAT3. Reduced levels of phosphorylated Erk1/2 were also seen under the influence of
XL-184, in line with previous reports of the effects of XL-184 on neuroblastoma [337] and the
prediction from the cell free assay offered by Uitdehaag et al. [257] (see also figure 4 for more
targets and their function). This hints to the mechanisms by which the drug combination
could drive the CT26.WT cells into apoptosis.
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6.4 Translational approach, in vivo
The question how to best augment particle therapy can only be answered by including the
tumor (micro)environment and the immune system [45,338]. The most difficult, highly treat-
ment resistant diseases are prime targets for heavy ion cancer therapy [339]. The 4T1 model in
BALB/c mice we used here is known to be p53 negative [333], does not respond to irradiation
with apoptosis [328] and did not appear to undergo apoptosis in our experiments (see above).
It can not be cured with 60 Gy of x-ray irradiation [259], has few mutations, is therefore less
immunogenic [11] and kills animals with lung metastases in 4 weeks. This is reflecting a tough
situation in the clinic, and therefore the 4T1 model is already appreciated by the heavy ion
community [339].
The drugging with Chloroquine, XL-184 and CDDO-Me per animal chow at low doses (see
methods) was applied to 4T1 tumor bearing mice starting at day 10 in the first experiment
and at day 5 in the second experiment with groups narrowed down to the diets containing
XL-184 (figures 17 and 18). Key results in brief:
• Markedly reduced tumor growth in the XL-184 treated groups.
• No apparent reduction in lung metastases in most animals, some animals poten-
tially did respond, but no overall change.
6.4.1 Interpretation of the results
Tumor growth
Without drugs, x-ray irradiation did lead to some minor tumor growth retardation, in line
with the results of Verbrugge et al. [328] (figure 19). XL-184 markedly reduced tumor growth
despite the low dose of 10 mg/kg per mouse and day (figure 19). In the transcriptome of
4T1, it can be seen that two actionable drug targets of XL-184, the tyrosine kinases Axl and
Met, are overexpressed comparable to CT26.WT cells [303]. XL-184 can inhibit all Receptor
Tyrosine Kinases shown in figure 1 and the tyrosine kinases Src and Erk (figure 1) [257]. While
Met is long known for its notorious role in cancer (https://resources.vai.org/Met/Index.aspx),
Axl gained popularity more recently (see figure 1) e.g. in conferring resistance to targeted
drugs [62,340,341]. Other XL-184 drug targets [257] are expressed to a lower extent in 4T1: Brk1,
Ddr1, Lck, Lyn, PDGFR-α, Tnk1 and Tyro3. Drug targets expressed in 4T1 as seen in the
transcriptome but not targeted by XL-184 are FGFR and Her-2 [342], pointing to further op-
timizations. Histological analyses like staining for phosphorylation states of molecules shown
in figure 1 and screen cell types present in the tumor will help to see if this growth sup-
pression was based on direct effects on tumor cells, immune mediated or maybe both. The
extent of growth reduction enabled by XL-184 seen here was comparable to the recent results
of Wolchok et al. with 4T1 mice treated with dual checkpoint (CTLA-4, PD-1) and PI3Kγ
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inhibition [120].
Remarkably, in the drugged mice, the tumors of the mice which also received irradiation
were apparently growing slightly faster toward the end of the experiment (figure 19). Even
though this difference was small and non significant, it probably should be not completely
ignored, as it is reminding of the results of Cui et al., who reported increased phosphorylation
of Akt and STAT3 and EMT after x-ray irradiation [135]. It can not be completely excluded
that x-ray irradiation was partly overriding the pharmacological intervention (see figure 1 for
a possible mechanism).
Lung Metastases
The immune modulatory properties reported for chloroquine, CDDO-Me and XL-184 (see
introduction) were not sufficient to reduce lung metastases count in combination with and
without irradiation (figure 23). Lung metastasis in the 4T1 model is clearly dependent on
myeloid cells [120,221,225]. The drug combination was also directed against myeloid cells [263,287]
(see introduction, figures 1 and 3). The activity of the drugging regimen against Akt [170] and
Erk1/2 [122] (see figure 18) was thought to reduce levels of G-CSF, and consequently, levels
of the myeloid cells in question [122,170,255] (see figure 1 [Erk1/2 -> G-CSF -> MDSC]). Con-
sidering the effect of radiation on tumor growth kinetics under drugging conditions (figure
19), this lack of efficacy could eventually be attributed to the influence of x-ray irradiation
on myeloid cell levels, and it is acknowledged to be (one of many) crucial open challenges
awaiting pharmacological solutions [343]. A closer examination of the serum samples on growth
factors and cytokines including G-CSF will probably reveal more insights.
6.5 The Particle Perspective
A key question is of course, if carbon ion irradiation would be more efficient in local control
and metastasis reduction by immunological means [344]. Given the results concerning tumor
growth, lung metastasis and the role G-CSF - induction, it is interesting how carbon ion ir-
radiation would influence the phosphorylation states of Akt [170]. In preliminary experiments,
we found no increase in Akt and Erk phosphorylation after carbon ion irradiation, a finding
also encountered by other researchers [314,345,346]. Given Therefore, it can be estimated that
carbon ion irradiation would demonstrate a more beneficial behavior in the 4T1 model, in
line with the immune activating properties of particle irradiation [145,344,347]. Irradiation of
human skin was recently shown to have immune suppressive properties [348,349]. However, as
the depth dose profile of carbon ion irradiation is inversed compared to x-ray [350], resulting in
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much smaller skin doses (and fewer or no skin reddening at all), the immunological effects of
particle irradiation could even be superior to x-ray.
The radiotherapy field in general is now undertaking massive efforts toward combined treat-
ments [256] including immunotherapy [153,226]. The immunotherapy field on his behalf is adopt-
ing methods to improve immunotherapy with small molecules [52,120] and radiation [351]. The
small molecule drug XL-184 alone was at least as effective as nivolumab (anti PD-1) for pa-
tients with poor prognosis [352]. Combining the versatile features of different therapy measures
in the frame of determined, structured and sustained efforts, will enable to vastly improve
patient benefit from particle therapy.
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7 Methods
7.1 Cell Culture
CT26.WT, 4T1 and B16-F10 cells were purchased from ATCC. CT26.WT and 4T1 cells
were expanded in RPMI (Millipore), supplemented with 9,6% FBS (Biochrom) and +1%
Penicillin/Streptomycin to yield a cryostock of cells used after few passages for the experi-
ments. B16-F10 cells were cultivated in DMEM (Biochrom) also supplemented with 9,6% FBS
(Biochrom) and +1% Penicillin/Streptomycin. Cells were passaged shortly before reaching
confluence.
7.2 Drug treatment of Cells
Cells were incubated for 20 h with Medium supplemented with Drugs in DMSO or Water typ-
ically using a 1:1000 to 1:2000 dilution and irradiated with 15 Gy. Chloroquine was purchased
from Sigma and dissolved in PBS to yield a 10 mM Solution, XL184 Malate and CDDO-Me
were purchased from Selleckchem, diluted to 10 mM and 300 µM in DMSO, respectively and
stored at -80 C. RPMI supplemented with 10 % Fetal Calf Serum and Penicillin/Streptomycin
was admixed with stock solutions of drugs at the appropriate ratios (1:3000 to 1:1000) to yield
the indicated concentrations.
7.3 Flow Cytometry
Cells were removed from the culture vessels and petri dishes with Accutase after washing
with PBS, keeping the supernatant, eventually containing apoptotic cells. After Accutase
incubation, the dissociated cells were collected using the supernatant from the specific probe
using no pipetting but just careful swapping of liquids to keep shear stress as absent as possible.
Staining was carried out carefully with fewer than 1 Million Cells with antibodies diluted in
Staining Buffer for the respective molecules.
7.3.1 Staining for Apoptosis and Necrosis
Staining with DAPI and Annexin-V is a standard method for the characterization of necrosis
and apoptosis. The blue fluorescence of the DNA binding dye DAPI can be measured after
excitation with light in the violet (405 nm) part of the spectrum, but only in cells with a
membrane which is permeabilized by cell membrane damage, which is the hallmark of necrosis.
DAPI is not able to penetrate intact cell membranes. Therefore, viable cells are DAPI negative.
Upon apoptosis, phosphatidylserine, which is prevalent on the inner part of the membrane,
is turned to the outer leaflet on the membrane. Annexin-V has a high binding affinity to
phosphatidylserine, by means of the coordination of calcium with phosphate residues. The
staining buffer therefore is prepared to contain some amount of Ca2+. Therefore, the staining
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Buffer was prepared supplementing 1 liter Millipore Water with 10 ml 1 M HEPES, 8,18
g NaCl and 368 mg CaCl2 * 2 H2O. It has been observed that apoptotic cells also have a
tendency to non specific binding (data not shown). Therefore, to evaluate surface molecules
like MHC-I (H2-kD), a gating strategy was devised to select cells which were both DAPI and
Annexin-V negative. In earlier experiments, instead of DAPI, Propidium Iodide was used,
mainly with the CT26.WT cells, which has a flourescence emission in the red and infrared
part of the spectrum. The FACS gating strategy was inclining to prefer DAPI, in order to
leave the red channel to the evaluation of surface molecules. Additionally, the stainings with
DAPI had a somehow cleaner appearance with more distinct populations of living versus dead
cells.
7.3.2 Staining for surface molecules
Antibodies used were: MHC-I (H2-kD, clone SF1-1.1) (BD Bioscience, Heidelberg), and
CD95/Fas (eBioscience, Clone Jo2) and Annexin-V conjugated to FITC (eBioscience). After
centrifugation at 300 g, cells were resuspended in Staining Buffer containing 1 µg DAPI and
secondary antibodies donkey against rat conjugated to APC, goat anti rabbit conjugated to
Alexa Fluor 488 or APC-Cy7 (Santa Cruz, Heidelberg Germany) depending on the respec-
tive experiment. Preferably, directly conjugated antibodies were used in later experiments,
as this is allowing to spare an additional washing step, further reducing overall shear stress.
Nonetheless, in FACS-Histograms, after effective radiation doses and drugging, a lot of smaller
particles can be found, likely consisting of cell fragments from apoptotic cells, thus potentially
evading analysis. After staining, the cells were subjected to flow cytometric measurements
using a FACSCanto II (BD Bioscience).
7.4 Western Blotting
Snap frozen cell samples (LN) were lysed in RIPA Buffer. This solution was supplemented
with 1 mM PMSF (Sigma) from a 250x Solution in 2-propanol, and additional Protease /
Phosphatase Inhibitor from Pierce (with EDTA). Protein concentration was determined via
Bradford Test in duplicates from triplicates using the Roti-Quant - Solution from ROTH,
Karlsruhe according to the indicated protocol, with the samples diluted 1:200 in the RIPA
Buffer without PMSF. As Protein Standard served BSA from Pierce. The protein standard
was diluted from the samples in the range of 5, 10, 20 and 40 µg/ml to serve as standard
solutions for the bradford test. The Proteins were separated on Any kD Gels with 10 wells
from BioRad, Bio-Rad Laboratories GmbH Heidemannstrasse 164 (Order No. 4569033), after
dilution in SDS PAGE sample buffer containing 20% mercaptoethanol. The gels loaded with
7.5 to 20 µg protein were subjected to Gel Electrophoresis at 400 mA using the MiniProtean
tank System from BioRad, using Polyvinylidenedifluoride (PVDF) membranes from Merck,
Darmstadt. The membranes were blocked in 2 % milk powder in TBST for at least two hours,
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followed by incubation with antibodies from Cellsignaling, Schuttersveld 2, 2316 ZA Lei-
den, Netherlands and secondary anti - rabbit antibodies from Sigma-Aldrich (Sigma-Aldrich
Chemie, Taufkirchen) at a concentration of 1:10 000. The resulting blots were developed with
the ECL system from thermo fisher. The ECL-treated membranes were quantified using a
camera system Fusion FX7 from Vilber Lourmat, Eberhardzell. The used antibodies and
their respective dilutions in 2 % Milk powder in TBST buffer were the following:
Antibodies for evaluation of phosphorylation states were from Cellsignaling:
Phospho-Akt (Ser473) (D9E) 4060: 1:1000;
Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E) 4370: 1:2000;
Phospho-Stat3 (Tyr705) (D3A7): 1:500.
Antibodies for evaluation of the levels of anti - apoptotic molecules were from Cellsignal-
ing:
Bcl-xL (54H6) mAb 2764: 1:2000;
Mcl-1 (D35A5) mAb 5453: 1:500;
Survivin (71G4B7) mAb 2808: 1:500.
The antibody for the housekeeping gene vinculin was from santa cruz: sc-5573: 1:250
All primary antibodies used in western blot listed above were produced in rabbit.
7.5 x-ray irradiation of cells
Cell samples were irradiated with an 250 kV X-Ray tube from General Electrics and a cathode
current of 16 mA. Low energy X-Rays were filtered with 7 mm Be, 1 mm Al and 1 mm Cu.
The applied dose was measured with a SN4 Dosimeter (PTW Freiburg) using an ionization
chamber placed directly under the sample. The dose rates used were between 1.5 and 3
Gy/min.
7.6 Carbon Ion Irradiation
Irradiation with carbon ions was done with the UNILAC linear accelerator furnishing carbon
ions with 6.5 MeV/u, the energy on target was 4.0 MeV/u with a LET in H2O of 325 keV/mum
for the data presented in figure 5. The energy of the particles presented in figure 11 was 11.4
MeV/u, the energy on target was 9.9 MeV/u with a LET in H2O of 168 keV/µm. Two days
before irradiation, the cells were seeded in petry dishes from Nunc on a surface of 35 cm2 at a
density of about 80 000 cells per vessel. The radiation doses applied with the UNILAC were
calculated as usual [353–355].
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7.7 Drugging of Animals
All animal experiments were carried out by the center for translational oncology, TRON,
in Mainz. Animals were drugged with a purified ingredient diet prepared by Researchdiets
Inc. (New Brunswick, USA) containing 66.6 mg/kg Cabozantinib malate salt - an approach
used successfully by James Hodge et al. using the MC38-CEA model in B57/BL6 mice [263].
Cabozantinib malate salt was purchased from LC-Labs (Woburn, USA). 66.6 mg/kg Chloro-
quine diphosphate from Aldrich and 50 mg/kg CDDO-Me from Selleckchem (Distributor:
Absource Diagnostics GmbH, Munich), alone and combined. Glyceryl trioctanoate 37.5 ml
and 10 ml Ethanol per kg of diet were used as an adjuvant to dissolve CDDO-Me to ensure
appropriate mixing with the diet compounds according to the advice / recipe of the inventor,
Dr. Sporn (personal communication). Each diet was mixed with traces of stains in different
colors to ensure appropriate feeding during the experiment. After mixing, the diet was pel-
leted to prevent access to air and possible compound degradation, with the heat produced
upon pelleting evaporizing the added ethanol. The product was packed in aluminum coated
resealable foil bags at 500 g per bag. The bags were vapor sterilized with H2O2 before en-
tering the barrier facility. However, the animals were behaving differently encountering the
diet with some animals responding well and some rather inferior upon diet change (appar-
ently discernible to groups of mice in different cages). Additionally, some mild weight loss of
5-10 % was encountered in animals receiving CDDO-Me- but not XL-184 treated diet com-
pound, contrariwise to any publication in the field in at least five mouse models [285]. This
could be a peculiarity of the BALB/c strain. The dosing used for XL-184 and Chloroquine,
resulting in about 10 mg/kg per mouse per day is in the lower range of concentrations used,
with other experimentators using as much as 3-10fold doses, hence representing a low dose
drugging [239,356].
7.8 Irradiation of animals
Animals were irradiated using a 320 kV X-Ray tube from X-Strahl equipped with a thoraeus
filter consisting of 1.5mm Al, 0.25mm Cu and 0.75mm Sn. The irradiation was carried out
with irradiation from above using a beam collimation system. Mice were kept under anesthesia
during irradiation, non - irradiated mice were anesthetized equally.
7.9 Metastases count
After sacrifice of the mice via cervical dislocation, mice were resected, the trachea were pre-
pared removing skin, muscle and glandular tissue. Trachea were injected with 300 µl of blue
ink, the injection site closed with forceps and the lung quickly removed. The lungs were
placed in 4 ml Fekete solution at 4 degrees celsius over night. Visible metastases were counted
(see figure 20) and the lungs transferred to GSI in histofix (information obtained from TRON
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GmbH).
Figure 20: Image of a lung to illustrate the method used to count lung metastases. Image
Courtesy: TRON GmbH, Mainz
7.10 Transcriptome analysis
For transcriptome analysis, a mouse reference genome (mm9) was indexed and the RNA -
sequence data of the transcriptomes of 4T1, B16-F10 and CT26.WT was aligned with bowtie.
The resulting data was transformed to a table using SAMMate. The transcriptome data used
here is available at http://sra.dbcls.jp.
7.11 Statistical analysis
Graphpad Prism for Apple from GraphPad Software, La Jolla California USA, www.graphpad.com
was used. For statistical analysis see Figures 4,5,6 (error bars represent the standard deviation
of three measurements from one representative experiment). For figures 16, and 18 statistical
analysis is based on two independent experiments with at least 8 animals per group.
PhD Thesis
8 List of Abbreviations 44
8 List of Abbreviations
PBS for cell culture was used as supplied from Biochrom.
RPMI for cell culture was used as supplied from Biochrom.
ATP Adenosine triphosphate
ATCC American Type Culture Collection
Axl Tyrosine-protein kinase receptor UFO
B16-F10 Murine melanoma cell line capable of lung metastasis (slower than 4T1).
Bcl-2 B-cell lymphoma 2
BCl-XL B-cell lymphoma-extra large
Bim Bcl-2-like protein 11 (pro apoptotic)
Brk1 Probable protein BRICK1
Btk Bruton’s tyrosine kinase
CAR-T-Cells Chimeric antigen receptor T cells
CC Cell cycle
CCL2 Chemokine (C-C motif) ligand 2
c-Met Hepatocyte growth factor receptor (HGFR), also known as the c-Met oncogene
CD Cluster of Differentiation / Cluster of Designation / Classification determinant
CDDO-Me from Selleckchem was diluted in DMSO from Roth for stock solutions for cell
experiments and forwarded as received to researchdiets for in vivo experiments.
Ddr1 Discoidin domain receptor family, member 1
CSC Cancer stem (like) cells
CT26.WT Murine colon cancer cell line, chemically induced.
CTLA-4 Cytotoxic T-lymphocyte-associated protein 4 (CD152)
DAPI 4’,6-Diamidino-2-phenylindole
DMEM Dulbecco’s Modified Eagle’s Medium
DMSO Dimethyl sulfoxide
PhD Thesis
8 List of Abbreviations 45
DNA Deoxyribonucleic acid
DR5 Death receptor 5
EMT Epithelial Mesenchymal Transition
Erk1/2 Extracellular signal regulated kinases, (subgroup of MAPK)
FACS Fluorescence-activated cell scanning
FAP Fibroblast activation protein
Fas No genuine abbreviation for this "death receptor". Based on the name of an antibody
termed "anti Fas" (CD95), before the gene was discovered.
FBS Fetal bovine serum
FGFR Fibroblast growth factor receptors
Flt-3 Fms like tyrosine kinase 3, fetal liver kinase-2, CD135
G-CSF Granulocyte-colony Stimulating Factor
Glyceryl trioctanoate was used as an adjuvant for the preparation of the drugged research
diet and was purchased from Sigma in the highest possible quality.
GSH Glutatione
GSK-3 Glycogen synthase kinase 3
Gy Gray (1 Gy = 1 J/kg)
Her-2 Receptor tyrosine-protein kinase erbB-2, human epidermal growth factor receptor 2,
(CD340)
HGF Hepatocyte growth factor
HMGB1 High mobility group box 1
HMVEC Human microvascular endothelial cells
IDO Indoleamine 2,3 - dioxygenase
IFN Interferon, a class of key cytokines in antitumor defense
IAP Inhibitor of apoptosis
Kit Stem cell growth factor receptor, CD117, tyrosine-protein kinase Kit
KPC mice K-rasLSL.G12D/+; p53R172H/+; PdxCre mice
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LC3 Microtubule-associated proteins 1A/1B light chain 3A
LC3-GFP-RFP LC3 coupled to green flourescent protein and red fluorecent protein
Lck Lymphocyte-specific protein tyrosine kinase
LN Liquid Nitrogen
LPS Lipopolysaccharide
Lyn Tyrosine-protein kinase Lyn, derived from Lck/Yes novel tyrosine kinase (Scr family)
M6PR Cation-dependent mannose-6-phosphate receptor
MAPK Mitogen Activated Protein Kinases
Mcl-1 Induced myeloid leukemia cell differentiation protein Mcl-1
MDSC Myeloid-derived suppressor cell
MEK MAP kinase-kinase, which activates ERK, MAPK/ERK kinase
Mer Proto-oncogene tyrosine-protein kinase
MHC Major histocompatibility complex
MLKL Mixed lineage kinase like
MSC Mesenchymal stromal cells
NFκB Nuclear factor kappa-light-chain-enhancer of activated B cells
Nrf-2 Nuclear factor (erythroid-derived 2)-like
PAGE Polyacryl amide gel electrophoresis
p53 Protein 53, a hallmark tumor suppressor gene
PBS Phosphate buffered saline
PD-1 Programmed cell death protein 1
PDGFR Platelet-derived growth factor receptors
PI3K Phosphatidylinositol-4,5-bisphosphate 3-kinase
PTEN Phosphatase and tensin homolog, a tumor suppressor encoded by the PTEN gene.
PUMA p53 upregulated modulator of apoptosis
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Raf Rapidly accelerated fibrosarcoma, a kinase family related to retroviral oncogenes
Ras Rat sarcoma (oncogene)
RET tyrosine kinase, abbreviation for "rearranged during transfection"
Ron Recepteur d’Origine Nantais, Macrophage-stimulating protein receptor
ROS Reactive Oxygen Species
RPMI Cell culture medium developed at the Roswell Park Memorial Institute
RTK Receptor Tyrosine Kinase
SBRT Stereotactic beam radiation therapy
SDS Sodium dodecyl sulfate
Src Proto-oncogene tyrosine-protein kinase Src (discovered in the Rous sarcoma virus)
STAT3 Signal transducer and activator of transcription 3
STING Stimulator of Interferon Genes
Tie2 Angiopoietin-1 receptor, CD202B
U2OS Osteosarcoma cell line
UNILAC Universal linear accelerator
TKI Tyrosine Kinase Inhibitor
TME Tumor microenvironment
TNF Tumor necrosis factor
Tnk1 tyrosine kinase, non-receptor, 1
TRAIL Tumor Necrosis Factor Related Apoptosis Inducing Ligand
Tyro3 Tyrosine-protein kinase receptor
VEGF-R Vascular endothelial growth factor receptor
XL-184, also known as Cabozantinib or Cometriq was purchased from Selleckchem as the
malate salt and dissolved in DMSO (Roth) for in vitro experiments. For in vivo exper-
iments, XL-184 was ordered from LC Laboratories, 165 New Boston Street, Woburn,
MA 01801 as the malate salt and forwarded to Researchdiets.Inc for preparation of the
drugged animal diet.
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4T1, B16-F10 and CT26.WT cells were purchased from the ATCC and maintained in
RPMI (CT26.WT, 4T1) and DMEM (B16-F10).
CDDO-Me from Selleckchem was diluted in DMSO from Roth for stock solutions for cell
experiments and forwarded as received to researchdiets for in vivo experiments.
DMEM Dulbecco’s Modified Eagle’s Medium was purchased from Biochrom.
DMSO Dimethyl sulfoxide was purchased from Roth.
FBS Fetal bovine serum was used as supplied from Biochrom to supplement the RPMI and
DMEM media.
Glyceryl trioctanoate was used as an adjuvant for the preparation of the drugged research
diet and was purchased from Sigma in the highest possible quality.
Glutathione was used as supplied by Sigma.
HMVEC Cells were purchased from Cell Applications, San Diego, CA 92121, USA and
maintained in a proprietary CADMEC / HMVEC medium.
KH2PO4 was supplied by Merck, Darmstadt.
Lipopolysaccharide was purchased from Sigma and prepared as a stock solution in DMSO
at one mg per one ml.
Na2HPO4 was supplied my Merck, Darmstadt.
NaCl was supplied by Roth, Karlsruhe.
PBS for cell culture was used as supplied from Biochrom.
Penicillin / Streptomycin for cell culture was used as supplied by life technologies, Darm-
stadt.
Phosphate buffered saline was used as supplied by Biochrom for cell culture. For im-
munohistology, PBS was prepared as a 10x solution from 2 liter purified water, 160 g
NaCl, 4 g KCl, 28.8 g Na2HPO4 and 4.8 g KH2PO4.
RPMI for cell culture was used as supplied from Biochrom.
RIPA Buffer consisted of 150 mM NaCl, 50 mM TRIS/HCl, 1 mM Na3VO4, 1 mM NaF,
10 g/l Nonident P40, 2,5 g/l Deoxycholate, 1 g/l SDS.
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SDS PAGE sample buffer was prepared from 0.035 g bromophenol blue, 7 ml glycerol, 6
ml SDS (10 %), 1 ml Tris-HCl (1 M, pH 6.7). 180 µl of this buffer was supplemented
with 20 µl of mercaptoethanol to prepare the sample buffer.
TBST buffer 100 ml Tris (1 M, pH 8.0, Sigma), 500 ml NaCl (3M) and 5 ml Tween 20 and
diluted with purified water to 1000 ml resulting in a 10x solution.
Water was used as supplied by the water purification device ELGA, Model PF4XXXXM1,
using demineralized water from the GSI compound.
XL-184, also known as Cabozantinib or Cometriq was purchased from Selleckchem as the
malate salt and dissolved in DMSO (Roth) for in vitro experiments. For in vivo exper-
iments, XL-184 was ordered from LC Laboratories, 165 New Boston Street, Woburn,
MA 01801, USA as the malate salt and forwarded to Research Diets, Inc. 20 Jules Lane,
New Brunswick, NJ 08901, USA for preparation of the drugged animal diet.
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